Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/176669
Title: | New potential weapons for refractory scleritis in the era of targeted therapy |
Author: | Fabiani, Claudia Sota, Jurgen Sainz de la Maza Serra, María Teresa Pelegrin, Laura Emmi, Giacomo Lopalco, Giuseppe Iannone, Florenzo Vannozzi, Lorenzo Guerriero, Silvana Gelmi, Maria Chiara Rigante, Donato Tosi, Gian Marco Hernández Rodríguez, José Cantarini, Luca |
Keywords: | Assaigs clínics de medicaments Inflamació Dianes farmacològiques Drug testing Inflammation Drug targeting |
Issue Date: | 17-Jan-2020 |
Publisher: | Hindawi |
Abstract: | Objective. To assess the efficacy of biologic drugs, beyond tumor necrosis factor- (TNF-) α inhibitors, in the management of noninfectious refractory scleritis, either idiopathic or associated with systemic immune-mediated disorders. Patients and Methods. This is a retrospective study assessing the efficacy of several biologic agents (rituximab, anakinra, tocilizumab, and abatacept) and the small molecule tofacitinib in the treatment of scleritis through assessment of scleral inflammation and relapses, as well as treatment impact on best-corrected visual acuity (BCVA) and safety profile. Results. Fourteen patients (19 eyes) were enrolled in the study. Scleritis inflammatory grading significantly improved from baseline to 3 months (p=0.002) and from baseline to the last follow-up visit (p=0.002). Scleritis relapses significantly decreased between the 12 months preceding and following biologic therapy (p=0.007). No differences regarding BCVA were observed (p=0.67). Regarding adverse events, only one patient developed pneumonia and septic shock under rituximab treatment. Conclusions. Our results, though limited to a low number of patients, highlight the effectiveness of different biologic therapies in the treatment of noninfectious refractory scleritis, showing to control scleral inflammation and allowing a significant reduction in the number of relapses. |
Note: | Reproducció del document publicat a: https://doi.org/10.1155/2020/8294560 |
It is part of: | Mediators of Inflammation, 2020, vol. 2020, p. 8294560 |
URI: | http://hdl.handle.net/2445/176669 |
Related resource: | https://doi.org/10.1155/2020/8294560 |
ISSN: | 0962-9351 |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
703626.pdf | 1.47 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License